Published in Cancer Weekly, July 11th, 2006
Study 1: CpG oligodeoxynucleotides (ODN) activate dendritic cells in vivo and induce a functional and protective vaccine immunity against a TERT-derived modified cryptic MHC class I-restricted epitope.
According to recent research from France, "The use of synthetic peptides derived from tumor-associated antigens is attractive for the development of antitumoral vaccines as far as strong adjuvants are found to render them immunogenic. We investigated the possibility to enhance the CD8 response against the human and mouse shared TERT572y ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.